BRIEF published on 08/28/2024 at 13:05, 1 year 10 months ago Rutherrin® Increases Efficacy of Chemotherapy for Lung Cancer Theralase® Technologies Inc. NSCLC Chemotherapy Rutherrin® Cisplatin
PRESS RELEASE published on 08/28/2024 at 13:00, 1 year 10 months ago Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer Theralase® announces significant enhancement of Cisplatin efficacy in chemotherapy resistant NSCLC using Rutherrin® drug formulation in preclinical studies. Combination therapy shows promising results for cancer treatment NSCLC Theralase Preclinical Studies Chemotherapy Rutherrin
BRIEF published on 08/21/2024 at 13:05, 1 year 10 months ago Theralase Demonstrates Activation of Rutherrin with Diabetes Drug Cancer Treatment Theralase Rutherrin Metformin ROS Production
BRIEF published on 08/21/2024 at 13:05, 1 year 10 months ago La théralase démontre l'activation de la rutherrine avec un médicament contre le diabète Traitement Du Cancer Theralase Rutherrin Metformine Production De ROS
PRESS RELEASE published on 08/21/2024 at 13:00, 1 year 10 months ago Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug Theralase Technologies Inc. announces innovative cancer treatment using Rutherrin activated by Metformin without light/radiation. Opens new patient care possibilities Innovation Theralase Technologies Inc. Cancer Treatment Rutherrin Metformin
BRIEF published on 08/12/2024 at 13:05, 1 year 10 months ago Theralase publie ses états financiers du deuxième trimestre 2024 Résultats Financiers Placements Privés Traitement Du Cancer Theralase Étude II
BRIEF published on 08/12/2024 at 13:05, 1 year 10 months ago Theralase Releases 2Q2024 Financial Statements Financial Results Private Placements Cancer Treatment Theralase Study II
PRESS RELEASE published on 08/12/2024 at 13:00, 1 year 10 months ago Theralase(R) Release’s 2Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the six-month period ended June 30, 2024. Conference call scheduled to review results. Study II progress and Break Through Designation update discussed Conference Call Financial Statements Theralase Technologies Inc. Break Through Designation Study II
BRIEF published on 07/08/2024 at 23:20, 1 year 11 months ago Theralase Closes $CAN 775,000 in First Tranche of Private Placement Private Placement Cancer Research Theralase Rutherrin Phase II Clinical Study
BRIEF published on 07/08/2024 at 23:20, 1 year 11 months ago Theralase clôture une première tranche de placement privé de 775 000 $CAN Placement Privé Recherche Contre Le Cancer Theralase Rutherrin Étude Clinique De Phase II
Published on 06/30/2026 at 02:00, 3 hours 11 minutes ago MedMira Reports Third Quarter Results FY2026
Published on 06/30/2026 at 00:05, 5 hours 6 minutes ago American Critical Minerals Announces Completion of Warrant Exercise Incentive Program
Published on 06/29/2026 at 23:46, 5 hours 25 minutes ago 1933 Industries Reports Third Quarter 2026 Financial Results
Published on 06/29/2026 at 22:01, 7 hours 10 minutes ago AIP Realty Trust Announces Voting Results of Annual General and Special Meeting of Unitholders
Published on 06/29/2026 at 15:00, 14 hours 11 minutes ago Infield Minerals Significantly Expands Land Holdings and Builds Regional Presence at the Detroit Gold Project in Utah
Published on 06/29/2026 at 22:47, 6 hours 23 minutes ago Correction d’un communiqué du 29.06.2026 22:05 CET/CEST - ABIVAX: Résultats positifs de la partie 2 de maintenance ABTECT démontrant bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les ...
Published on 06/29/2026 at 22:05, 7 hours 6 minutes ago ABIVAX: Résultats positifs de la partie 2 de l’essai de maintenance ABTECT démontrant bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les données de sécurité
Published on 06/29/2026 at 22:05, 7 hours 6 minutes ago Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory UC Patients and Strengthening the Phase 3 Maintenance Safety Database
Published on 06/29/2026 at 20:30, 8 hours 41 minutes ago Shelly Group SE: Annual General Meeting approves dividend of EUR 0.13 per share – shareholders approve all agenda items
Published on 06/29/2026 at 20:00, 9 hours 10 minutes ago IGEL Appoints James Millington as Field CTO for Healthcare in EMEA
Published on 06/29/2026 at 18:30, 10 hours 41 minutes ago Accor and H World Group expand long-term partnership across direct booking and loyalty platforms
Published on 06/29/2026 at 18:30, 10 hours 41 minutes ago Accor et H World Group : extension du partenariat de long terme aux plateformes de réservation directe et de fidélité
Published on 06/29/2026 at 17:45, 11 hours 26 minutes ago Succès de l’émission obligataire de 1,5 milliard d’euros
Published on 06/29/2026 at 17:45, 11 hours 26 minutes ago Déclaration hebdomadaire de rachat d'actions
